Thermo Fisher Scientific Positioned for Growth in PCR and CRO Markets

Thermo Fisher Scientific is prominently featured in recent industry analyses forecasting substantial growth within two key areas of its business: Polymerase Chain Reaction (PCR) technologies and pharmaceutical Contract Research Organization (CRO) services.

Coverage today highlights that the PCR market, encompassing qPCR, digital PCR, and multiplex testing, is expected to experience considerable expansion. Reports profile numerous companies within this dynamic sector, including Thermo Fisher, indicating a competitive landscape driven by advancements in diagnostic and research capabilities. This growing market reflects increased demand for sophisticated molecular testing solutions.

In parallel, the pharmaceutical CRO market is projected for significant growth, with forecasts estimating an increase from approximately $45.33 billion in 2025 to $83.31 billion by 2033. Thermo Fisher is identified as one of the key players in this expanding field, alongside other major CROs. This anticipated rise underscores the increasing reliance of pharmaceutical companies on external partners for research and development services, covering preclinical studies, clinical trials, and other essential R&D functions.

These market outlooks suggest a positive trajectory for Thermo Fisher Scientific, positioning the company to capitalize on expanding opportunities in both life science research tools and pharmaceutical development services. The dual focus on advancements in PCR technology and the robust growth of the CRO sector points to strategic alignment with critical trends in healthcare and biotechnology.